50
Participants
Start Date
October 2, 2023
Primary Completion Date
June 30, 2027
Study Completion Date
May 31, 2029
CF33-CD19 IT Monotherapy
Safety Run-In Phase: CF33-CD19 will be administered intratumorally on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.
CF33-CD19 IV Monotherapy
Safety Run-In Phase: CF33-CD19 will be administered intravenously on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.
CF33-CD19 IT Combination
Dose Escalation Combination Phase: CF33-CD19 will be administered intratumorally on Days 1 and 15 of each 28 day cycle.
CF33-CD19 IV Combination
Dose Escalation Combination Phase: CF33-CD19 will be administered intravenously on Days 1 and 15 of each 28 day cycle.
Blinatumomab
Blinatumomab will be infused via a 7-day continuous infusion from Days 2-9 and Days 16-23 of each 28-day cycle.
Hydroxyurea
Hydroxyurea will be orally administered daily.
RECRUITING
Roswell Park Comprehensive Cancer Center, Buffalo
RECRUITING
University of Pittsburgh Medical Center, Pittsburgh
RECRUITING
Emory Winship Cancer Institute, Atlanta
RECRUITING
University of Cincinnati, Cincinnati
RECRUITING
Northwestern, Chicago
RECRUITING
University of Nebraska Medical Center, Omaha
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
City of Hope, Duarte
Imugene Limited
INDUSTRY